Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

Clinica Chimica Acta

Volumn 405, Issue 1-2, 2009, Pages 49-52

  He, Yi Jing ^a,b   Zhang, Wei ^a   Chen, Yao ^a   Guo, Dong ^a   Tu, Jiang Hua ^a   Xu, Lin Yong ^a   Tan, Zhi Rong ^a   Chen, Bi Lian ^c   Li, Zhi ^a   Zhou, Gan ^a   Yu, Bang Ning ^a   Kirchheiner, Julia ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF ULM   (Germany)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Rifampicin; SLCO1B1

Indexed keywords

ATORVASTATIN; ORGANIC ANION TRANSPORTER 2; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOTYPE; HEPTANOIC ACIDS; HUMANS; KINETICS; MALE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; PYRROLES; RIFAMPIN; THYMIDINE; YOUNG ADULT;

EID: 67349229228     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.04.003     Document Type: Article

References (29)

1. Konig J., Cui Y., Nies A.T., and Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278 (2000) G156-164
2. Tirona R.G., Leake B.F., Merino G., and Kim R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276 (2001) 35669-35675
3. Kameyama Y., Yamashita K., Kobayashi K., Hosokawa M., and Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15 (2005) 513-522
4. Mwinyi J., Johne A., Bauer S., Roots I., and Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75 (2004) 415-421
5. Pasanen M.K., Neuvonen M., Neuvonen P.J., and Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16 (2006) 873-879
6. Kantola T., Kivisto K.T., and Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64 (1998) 58-65
7. Jacobsen W., Kuhn B., Soldner A., et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28 (2000) 1369-1378
8. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 (2004) 1140-1146
9. Lau Y.Y., Okochi H., Huang Y., and Benet L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34 (2006) 1175-1181
10. Lau Y.Y., Okochi H., Huang Y., and Benet L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316 (2006) 762-771
11. Lau Y.Y., Huang Y., Frassetto L., and Benet L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81 (2007) 194-204
12. Hochman J.H., Pudvah N., Qiu J., et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21 (2004) 1686-1691
13. Boyd R.A., Stern R.H., Stewart B.H., et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40 (2000) 91-98
14. Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
15. Vavricka S.R., Van Montfoort J., Ha H.R., Meier P.J., and Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36 (2002) 164-172
16. Letschert K., Faulstich H., Keller D., and Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91 (2006) 140-149
17. Xu L.Y., He Y.J., Zhang W., et al. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28 (2007) 1693-1697
18. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.L., and Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35 (2007) 1333-1340
19. Zhang W., He Y.J., Han C.T., et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 62 (2006) 567-572
20. Zhang W., Chen B.L., Ozdemir V., et al. SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 64 (2007) 346-352
21. Chung J.Y., Cho J.Y., Yu K.S., et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78 (2005) 342-350
22. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
23. Deng J.W., Song I.S., Shin H.J., et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18 (2008) 424-433
24. Gui C., Miao Y., Thompson L., et al. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584 (2008) 57-65
25. Jigorel E., Le Vee M., Boursier-Neyret C., Parmentier Y., and Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34 (2006) 1756-1763
26. Kato M., Chiba K., Horikawa M., and Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20 (2005) 236-243
27. Fan L., Zhang W., Guo D., et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83 (2008) 471-476
28. Kim R.B. Transporters and xenobiotic disposition. Toxicology 181-182 (2002) 291-297
29. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359 (2008) 789-799